Lineage Cell Therapeutics (LCTX) Common Equity (2010 - 2026)

Lineage Cell Therapeutics' Common Equity history runs 17 years deep, the most recent figure standing at $52.7 million for Q1 2026.

• On a quarterly basis, Common Equity fell 32.14% year-over-year to $52.7 million in Q1 2026; TTM through Mar 2026 was $52.7 million, a 32.14% decrease from a year earlier, with the FY2025 full-year figure at $43.3 million, down 43.72% from the prior year.
• Common Equity improved to $52.7 million in Q1 2026 per LCTX's latest filing, from $43.3 million in the prior quarter.
• Across five years, Common Equity topped out at $85.2 million in Q1 2022 and bottomed at $20.8 million in Q3 2025.
• The 5-year median for Common Equity is $69.0 million (2023), against an average of $65.1 million.
• Across the five-year window, Common Equity advanced 24.17% in 2024 and plunged 67.9% in 2025, its largest moves.
• Year by year, Common Equity stood at $71.9 million in 2022, then retreated by 13.78% to $62.0 million in 2023, then grew by 24.17% to $77.0 million in 2024, then slumped by 43.72% to $43.3 million in 2025, then gained by 21.57% to $52.7 million in 2026.
• Per Business Quant, the three latest LCTX Common Equity figures stand at $52.7 million (Q1 2026), $43.3 million (Q4 2025), and $20.8 million (Q3 2025).